Friday, December 14, 2018

Investorideas.com - Investor Ideas Adds New Stocks in #Cannabis and #Biotech $NTFU, $PYX, $BOSS.C, $MRNA

Investor Ideas Adds New Stocks in #Cannabis and #Biotech $NTFU, $PYX, $BOSS.C, $MRNA

Point Roberts, WA and Delta, BC - December 14, 2018 (Investorideas.com Newswire) Investorideas.com, a global news source and leading investor resource announces this week's additions to its global stock directories in cannabis and biotech.

Investorideas.com is a go-to destination for retail investors and tracks companies in high-profile trading sectors and makes ongoing additions to its stock directories for its followers and members. (https://www.investorideas.com/membership/)

New cannabis companies this week also cross over in the agriculture and life sciences sectors and include a nutraceutical company, an agriculture company and an asset growth company with links to cannabis sativa wellness formulas for body care, facial care and pain management.

The newest biotech company is involved in the discovery and development of messenger RNA (mRNA) therapeutics and vaccines.

This week's new Marijuana/Cannabis Stocks Added to the Investor cannabis stock directory:

NutraFuels, Inc. (OTCQB: NTFU) is a nutraceutical company with a line of CBD-infused products known by its in-house brand, NutraHempCBD. Using premium CBD hemp oil, its formulations are designed to promote overall health and wellness. NutraHempCBD products are intended for daily use with observed health benefits including anti-stress, anti-inflammation, calmness to sleep and stay asleep. NutraHempCBD uses its specialty process to decrease the particle size and uses nano nanoemulsion in its products. For example, its Joint and Pain Balm aids in the alleviation pain with a silky and soothing formulation. Studies suggest that the key ingredient, CBD, may reduce inflammation while interacting with neurotransmitters. The CBD-infused Face Cream is made with Shea Butter and works to maintain elasticity of the delicate facial tissue. CBD studies have shown anti-inflammatory properties as well as a reduction in acne.

Pyxus International, Inc. (NYSE: PYX) is a global agricultural company united behind a common purpose - to transform people's lives so that together we can grow a better world. With 145 years' experience delivering value-added products and services to businesses and customers, we are a trusted provider of responsibly-sourced, independently-verified, sustainable and traceable products and ingredients. Pyxus International offers high-quality, distinct brands and products on the cutting edge of innovation and entrepreneurship in the E-Liquids, industrial hemp, legal cannabis and leaf tobacco industries.

The Yield Growth Corp. (CSE:BOSS) is a cannabis asset growth corporation with assets in media, technology and products. Yield Growth owns 100% of Urban Juve Provisions Inc., which has a catalogue of over 50 cannabis sativa wellness formulas for body care, facial care and pain management and other therapeutic products. Urban Juve has registered for sale with Health Canada 26 products containing cannabis sativa hemp oil and has filed 11 provisional patent applications in the United States. Urban Juve's line of Ayurveda-inspired holistic skin care products are sold in Canada, with distribution agreements signed for the U.S. and Italy. Yield Growth enters the $3.7 trillion dollar global wellness economy with directors and officers who have experience at multi-billion dollar international companies including MAC Cosmetics, Aritzia, Skechers, Pepsi and Coca-Cola.

Learn more and sign up to hear other podcasts Or www.potcasts.ca

New Biotech Companies:

Moderna, Inc. (NasdaqGS: MRNA) pioneers the discovery and development of messenger RNA (mRNA) therapeutics and vaccines to direct the body's cells to produce intracellular or secreted proteins that can have a therapeutic or preventive benefit for both patients and healthy individuals.

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

About Investorideas.com - News that Inspires Big Investing Ideas

Investorideas.com is a recognized news source publishing third party news and press releases plus we create original financial content. Learn about investing in stocks and sector trends from Investorideas.com with our news alerts , articles , podcasts and videos talking about cannabis, crypto, technology including AI and IoT , mining ,sports biotech, water, renewable energy and more . Investorideas.com original branded content includes the daily Crypto Corner and Podcast, Play by Play sports and stock news column, Investor Ideas #Potcasts#Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change Podcast and the AI Eye Podcast and column covering developments in AI.

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer and disclosure info: https://www.investorideas.com/About/Disclaimer.asp.

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: https://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Learn more about our news, PR and social media services at Investorideas.com

https://www.investorideas.com/Investors/Services.asp

To sponsor our daily podcast for the month or to be an expert guest please contact us!

Contact Investorideas.com

800-665-0411

Friday, October 26, 2018

Investorideas.com - Investor Ideas Adds New #Nasdaq IPOs in #Biotech (Nasdaq: $ALLO, $EQ, $GH, $KOD, $PRNB, $YMAB) & Newly Listed #CSE Stocks

Investor Ideas Adds New #Nasdaq IPOs in #Biotech (Nasdaq: $ALLO, $EQ, $GH, $KOD, $PRNB, $YMAB) & Newly Listed #CSE Stocks

CSE-Listed Stocks in #Mining, #Energy and #Nanotech (CSE: $CRES, $DLRY, $KAL, $SENS, $SONA)

Point Roberts, WA and Delta, BC - October 26, 2018 (Investorideas.com Newswire) Investorideas.com, a global news source and leading investor resource announces this week’s additions to its global stock directories in biotech, mining, energy and nanotech.

Investorideas.com is a go- to destination for retail investors and tracks companies in high-profile trading sectors and makes ongoing additions to its stock directories for its followers and members . (https://www.investorideas.com/membership/)

New biotech companies are all recent Nasdaq IPO's and include biotech, oncology, biopharma and life sciences companies providing treatments for cancer, autoimmune and ophthalmic diseases.

The latest mining companies are all CSE-Listed and operate in Canada, while the newest energy company (also CSE-Listed), is a leading solutions provider to various sectors including the oil and gas industry.

Finally, the newest nanotech company Sona Nanotech Inc. (CSE: SONA), also crosses over into the biotech (life sciences) sector with their rod-shaped gold nanoparticles which are used in multiplex diagnostic testing platforms.

New Biotech Companies:

ALLOGENE THERAPEUTICS, INC. (NasdaqGS: ALLO) with headquarters in South San Francisco, is a clinical stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T-cell (AlloCAR T™) therapies for cancer.

EQUILLIUM, INC (NasdaqGM: EQ) is a biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium's initial product candidate, EQ001 (itolizumab), is a clinical-stage, first-in-class monocolonal antibody that selectively targets the novel immune checkpoint receptor CD6 and is designed to modulate T cells that drive immuno-inflammation. Itolizumab is a clinically-validated therapeutic with a favorable safety and tolerability profile. Equillium plans to advance EQ001 into clinical development in multiple indications of high unmet medical need and believes EQ001 has the potential to be a best-in-class disease modifying therapeutic.

GUARDANT HEALTH, INC. (NasdaqGS: GH) is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Its Guardant Health Oncology Platform is designed to leverage its capabilities in technology, clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs. In pursuit of its goal to manage cancer across all stages of the disease, Guardant Health has launched multiple liquid biopsy-based tests, Guardant360 and GuardantOMNI, for advanced stage cancer patients, which fuel its LUNAR development programs for recurrence and early detection. Since its launch in 2014, Guardant360 has been used by more than 5,000 oncologists, over 40 biopharmaceutical companies and all 27 of the National Comprehensive Cancer Network centers.

KODIAK SCIENCES INC. (NasdaqGM: KOD) is a clinical stage company developing innovative therapeutics to treat high prevalence ophthalmic diseases. We aspire to global leadership in ophthalmology through internal focus and by aggregating top talent, technologies, discoveries and ideas. Our Antibody Biopolymer Conjugate, or ABC Platform™, merges the fields of antibody-based and chemistry-based therapies and is at the core of Kodiak's discovery engine. In addition to its lead product candidate, KSI-301, a potential best in class molecule for age-related macular degeneration and diabetic retinopathy, Kodiak has leveraged its ABC Platform™ to build a pipeline of product candidates in various stages of development including KSI-501, a dual inhibitor ABC for the treatment of neovascular retinal diseases such as wet AMD and diabetic retinopathy. Kodiak is based in Palo Alto, CA.

PRINCIPIA BIOPHARMA INC. (NasdaqGS:PRNB) is a clinical-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology. Principia's proprietary Tailored Covalency® platform enables Principia to design and develop reversible and irreversible covalent, small molecule inhibitors with potencies and selectivities that have the potential to rival those of injectable biologics, yet maintain the convenience of a pill. PRN1008, a reversible covalent BTK inhibitor, is being evaluated in a Phase 2 clinical trial in patients with pemphigus, an orphan autoimmune disease, and in a Phase 2 clinical trial in patients with ITP, a rare hematological disease. PRN2246, a covalent BTK inhibitor which crosses the blood-brain barrier, has completed a Phase 1 clinical trial in healthy volunteers, and has been partnered with Sanofi for development in multiple sclerosis and, potentially, for other diseases of the CNS. PRN1371, a covalent inhibitor of Fibroblast Growth Factor Receptor (FGFR), is being evaluated in a Phase 1 trial in patients with solid tumors.

Y-mAbs THERAPEUTICS, INC. (NasdaqGS: YMAB) is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The Company has a broad and advanced product pipeline, including two pivotal-stage product candidates-naxitamab and omburtamab-which target tumors that express GD2 and B7-H3, respectively.

New Mining Companies:

Crest Resources Inc. (CSE: CRES) is engaged in the business of mineral exploration and the acquisition of mineral property assets in Canada. Its objective is to locate and develop economic precious and base metal properties of merit and to conduct its exploration program on the Red Metal Ridge Property. The Red Metal Ridge Property is comprised of six contiguous mineral titles covering an area of 1381.50 hectares, located 74 kilometres northwest of the town of Campbell River and 12 kilometres southwest of the town of Sayward on Vancouver Island, British Columbia, Canada.

Delrey Metals Corp. (CSE:DLRY) is an exploration stage mineral resources company whose principal business activities include acquiring, exploring and evaluating strategic energy mineral properties

Kal Minerals Corp. (CSE: KAL) is a Canadian junior mineral exploration company with a specific focus on properties in the New Westminster Mining Division of British Columbia, Canada. The Company's sole property, the Jack White Property, is comprised of four mineral tenures covering approximately 2,202 hectares approximately 13km northeast of Boston Bar, British Columbia.

New Energy Companies:

Sensor Technologies Inc. (CSE:SENS) - formerly Mooncor Oil and Gas Corp - is a leading solutions provider to various sectors including the oil and gas industry. With non-intrusive technologies including fiber-optic sensors and electric field mapping EFM systems. Sensor Technologies Corp is able to accurately measure changes that could negatively impact our client's operations. SENS F.O. sensors are a non-invasive tool for monitoring pipeline defects in real time. consist of non-intrusive sensors, monitor & software. SENS's EFM monitoring of isolated pit formation & growth using a non-permanent modular design based on electrical resistance measurements, monitoring locations may be placed hundreds of feet away from the sensors. Software operates in continuous or scheduled reporting modes. SENS's latest tech, is its leak detection system, for use in application such as Pipe sections at remote facilities Monitoring of Military, Scientific installations for corrosive liquids in harsh environments , in tank farms, pipe sections, Water leak detection in data centers & buildings.

New Nanotech Companies:

Sona Nanotech Inc. (CSE: SONA) is a nanotechnology life sciences firm that has developed two proprietary methods for the manufacture of rod-shaped gold nanoparticles. The principal business carried out and intended to be continued by Sona is the development and application of its proprietary technology for use in multiplex diagnostic testing platforms that will improve performance over existing tests in the market. Sona's gold nanorod particles are CTAB (cetyltrimethylammonium) free, eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. It is expected that Sona's gold nanotechnologies may be adapted for use in applications, as a safe and effective delivery system for multiple medical treatments, pending the approval of various regulatory boards including Health Canada and the FDA.

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

About Investorideas.com - News that Inspires Big Investing Ideas

Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Learn more about our news, PR and social media services at Investorideas.com

https://www.investorideas.com/Investors/Services.asp

To sponsor one of our podcasts or columns or be a guest call us today!

Contact Investorideas.com

800-665-0411

Thursday, October 18, 2018

Investorideas.com - #HealthcareStock News: China Infrastructure Construction Corp. (OTCPK: $CHNC) and America's Advanced Wellness Centers, LLC (AAWC) Enter Into Acquisition Agreement

#HealthcareStock News: China Infrastructure Construction Corp. (OTCPK: $CHNC) and America's Advanced Wellness Centers, LLC (AAWC) Enter Into Acquisition Agreement

HOUSTON, TX - October 18, 2018 (Investorideas.com Newswire) China Infrastructure Construction Corp. (OTC: CHNC) www.thechnc.com is pleased to announce the acquisition of America's Advanced Wellness Centers, LLC (AAWC). AAWC is a five-part medical clinic/clinical research company consisting of Family Medicine, Obstetrics-Gynecology, Medical Weight Loss, a Wholesale/Direct-Mail Pharmacy, and a Clinical Research Center. AAWC brings multi-million dollar contracts with the biggest pharmaceutical companies in the world, like Pfizer and Allergan, to name a few. President & CEO Elizabeth Hernandez says, "Aside from being at the forefront of finding cures and treatments for disease, the acquisition of AAWC's clinical research arm allows CHNC to have another revenue-generating model that will allow some its members to receive medical care at little or no cost. We expect more acquisitions like that of AAWC in the future as clinics/doctors see the quality of care CHNC provides its members and the quality of life its doctors are experiencing as a result of using CHNC's model of care. We are always looking to build shareholder value and this acquisition does just that."

The acquisition, which has been approved by the board of directors, is subject to certain closing conditions, including OTC approval, approval by stockholders of China Infrastructure Construction Corp. (CHNC), minimum cash balance of CHNC at closing, and other customary closing conditions.

About China Infrastructure Construction Corp. (CHNC)

China Infrastructure Construction Corp. (CHNC), through its wholly-owned subsidiary Hippocrates Direct Healthcare, Inc., is innovating healthcare by redefining the doctor-patient relationship. Direct access to physicians, by its clients, is the cornerstone of Hippocrates. It is understandable why patients and providers are both dissatisfied with the way medical care is delivered. From a patient's perspective, medical care is a vast web of bureaucracy that is expensive, time consuming, and lacking in considerations for patient care and comfort. The care provided is minimal, five to ten minutes per visit at best, and one to two problems per visit as well. As a result, quality of care and results are sorely lacking—this is the TRUE cause of the crisis we face in medical care today. Hippocrates Direct will correct this problem. Hippocrates Direct offers concierge medicine through its membership-based model. The company will own and staff individual clinical facilities initially in the Houston Metro area and will expand nationwide. More information can be found online at www.thechnc.com

Hippocrates Direct Healthcare, Inc. is a wholly-owned subsidiary of China Infrastructure (CHNC). China Infrastructure's common stock trades on the OTC Markets under the ticker symbol "CHNC."

Safe Harbor Statement

The information posted in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by use of the words "may," "will," "should," "plans," "explores," "expects," "anticipates," "continue," "estimate," "projects," "intends," and similar phrases. Forward-looking statements involve risks and uncertainties that could cause actual results to differ from those projected or anticipated. These risks and uncertainties include, but are not limited to, general economic and business conditions, effects of geopolitical conditions, competition, changes in technology and methods of marketing, and various other factors beyond the company's control.

Hippocrates Direct Healthcare™ and the Hippocrates Direct Healthcare™ logo are all trademarks or registered trademarks of Hippocrates Direct Healthcare™, Inc.

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ Disclosure this is a paid for news release

Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

BiotechIndustryStocks.com - A Leading Global Investor Website for Biotech Industry Stocks

BiotechIndustryStocks.com - investing ideas in biotechnology stocks, medical technology and life sciences

Like Biotech Stocks? View our Biotech Stocks Directory

Get News Alerts on Biotech Stocks

Friday, October 12, 2018

Investorideas.com - Investor Ideas adds Nasdaq #Biotech #IPOs and CSE #Mining IPO Stocks to Directories (NASDAQ: $ADIL), (NASDAQ: $ALLK) (NASDAQ: $AQST), (CSE: $ZX.C)

Investor Ideas adds Nasdaq #Biotech #IPOs and CSE #Mining IPO Stocks to Directories (NASDAQ: $ADIL), (NASDAQ: $ALLK) (NASDAQ: $AQST), (CSE: $ZX.C)

Point Roberts, WA and Delta, BC - September 21, 2018 (Investorideas.com Newswire) Investorideas.com, a global news source and leading investor resource announces this week's additions to its global stock directories in biotech and mining.

Investorideas.com is a go- to destination for retail investors and tracks companies in high-profile trading sectors and makes ongoing additions to its stock directories for its followers and members . (https://www.investorideas.com/membership/)

The newest companies in biotech are all Nasdaq IPO listings from within the past few weeks and include pharmaceutical, medical device and biopharma companies looking to treat a variety of diseases and unmet medical conditions/needs.

The latest mining company is a recent CSE listing that is exploring and developing properties in Quebec and BC, Canada.

New Biotech Companies

ADIAL PHARMACEUTICALS, INC. (NasdaqCM: ADIL) is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company's lead investigational new drug candidate, AD04, is a genetically targeted therapeutic agent for the treatment of alcohol use disorder (AUD). A Phase 2b clinical trial of AD04 for the treatment of AUD showed promising results in reducing frequency of drinking, quantity of drinking and heavy drinking (all with statistical significance), and no overt safety concerns (there were no statistically significant serious adverse events reported). The Company plans to commence a Phase 3 clinical trial using AD04 for the potential treatment of AUD in subjects with certain target genotypes, which are to be identified using the Company's proprietary companion diagnostic genetic test. AD04 is also believed to have the potential to treat other addictive disorders such as opioid use disorder, gambling, and obesity.

ALLAKOS INC. (NasdaqGS:ALLK) is a clinical stage company developing antibodies that target immunomodulatory receptors present on immune effector cells involved in allergic, inflammatory, and proliferative diseases. The Company's lead antibody, AK002, targets Siglec-8, an inhibitory receptor selectively expressed on human mast cells and eosinophils. Inappropriately activated eosinophils and mast cells have been identified as key drivers in a number of severe diseases affecting the gastrointestinal tract, eyes, skin, lungs and other organs. AK002 has completed two Phase 1 trials, one in healthy volunteers and a single ascending dose trial in patients with indolent systemic mastocytosis. AK002 demonstrated pharmacodynamic activity in both trials and in the trial involving patients with indolent systemic mastocytosis, patients reported improvements in their symptoms. AK002 is being tested in a Phase 2 trial for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis. In addition, Allakos is conducting multiple-dose trials with AK002 in chronic urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis.

AQUESTIVE THERAPEUTICS, INC. (NasdaqGM: AQST) is a specialty pharmaceutical company focused on identifying, developing and commercializing differentiated products to address unmet medical needs. Aquestive Therapeutics has a late-stage proprietary product pipeline focused on the treatment of CNS diseases, and is working to advance orally-administered complex molecules that it believes can be alternatives to invasively-administered standard of care therapies. As the leader in developing and delivering drugs via its PharmFilm® technology, Aquestive Therapeutics also collaborates with pharmaceutical partners to bring new molecules to market in differentiated and highly-marketable dosage forms.

CONSTELLATION PHARMACEUTICALS INC (NasdaqGS:CNST) is a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. With a decade of experience in the field, the Company has a deep understanding of how epigenetic regulators modulate gene expression in cancer cells and in the tumor and immune microenvironment. Constellation is translating these insights to advance the Company's two lead clinical programs, the EZH2 inhibitor CPI-1205 for metastatic castration-resistant prostate cancer and solid tumors and the BET inhibitor CPI-0610 for myelofibrosis, and to explore other novel targets for which cancer epigenetics may enhance outcomes over currently available treatment options.

CRINETICS PHARMACEUTICALS, INC. (NasdaqGS:CRNX) is a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly, an orphan disease affecting more than 25,000 people in the United States. The company is also developing other oral nonpeptide somatostatin agonists for hyperinsulinism and neuroendocrine tumors, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. Crinetics was founded by a team of scientists with a track record of endocrine drug discovery and development.

ESTABLISHMENT LABS HOLDINGS INC. (NasdaqCM:ESTA) is a global medical technology company focused on improving patient safety and aesthetic outcomes, initially in the breast aesthetics and reconstruction market, by designing, developing, manufacturing and marketing an innovative portfolio of silicone gel-filled breast implants, branded as Motiva Implants®, the centerpiece of the MotivaImagine® platform. Motiva Implants® are produced at two FDA compliant state-of-the-art facilities in Costa Rica and currently sold in over 60 countries through exclusive distributors or the Company's direct salesforce. In March 2018, Establishment Labs received approval for an investigational device exemption (IDE) from the FDA and initiated the Motiva Implant® clinical trial in the United States in April 2018. In addition to Motiva Implants®, Establishment Labs' product and technologies portfolio includes the Divina® 3D Simulation System, Puregraft and MotivaImage® Centers.

LIQUIDIA TECHNOLOGIES INC (NasdaqCM: LQDA) is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the lives of patients. PRINT® is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. Currently, Liquidia is focused on the development of two product candidates for which it holds worldwide commercial rights: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia's lead product candidate, LIQ861, currently being evaluated in a Phase 3 clinical trial (INSPIRE), is designed to improve the therapeutic profile of treprostinil by enhancing deep-lung delivery and achieving higher dose levels than current inhaled therapies by using a convenient, disposable dry powder inhaler. LIQ865, for which Liquidia has recently completed a U.S. Phase 1b clinical trial, is designed to deliver sustained-release particles of bupivacaine, a non-opioid anesthetic, to treat local post-operative pain for three to five days through a single administration. In addition to developing its own product candidates, Liquidia collaborates with leading pharmaceutical companies to develop their own product candidates across a wide range of therapeutic areas, molecule types and routes of administration, leveraging Liquidia's PRINT® technology.

PROVENTION BIO, INC (NasdaqCM:PRVB) is a clinical-stage biopharmaceutical company leveraging a transformational drug development strategy that is focused on the prevention or interception of immune-mediated disease. Our diverse portfolio was assembled with product candidates that have undergone clinical testing but may have been underdeveloped or deprioritized assets at other companies. Provention's mission is to in-license, transform and develop clinical-stage, or nearly clinical-stage, therapeutic candidates targeting the high morbidity, mortality and escalating costs of autoimmune and inflammatory diseases including: type 1 diabetes (T1D), Crohn's disease, ulcerative colitis, lupus, and certain life-threating viral diseases.

REPLIMUNE GROUP, INC. (NasdaqGS:REPL) headquartered in Woburn, MA, was founded in 2015 to develop the next generation of "oncolytic immunotherapies" for the treatment of cancer. Replimune is developing novel, proprietary therapeutics intended to improve the direct cancer-killing effects of selective virus replication and the potency of the immune response to the tumor antigens released. The Company's Immulytic™ platform is designed to maximize systemic immune activation, in particular to tumor neoantigens, through robust viral mediated immunogenic tumor cell killing and the delivery of optimal combinations of immune-activating proteins to the tumor and draining lymph nodes. The approach is expected to be highly synergistic with immune checkpoint blockade and other approaches to cancer treatment. Replimune intends to progress these therapies rapidly through clinical development in combination with other immuno-oncology products with complementary mechanisms of action

RUBIUS THERAPEUTICS, INC. (NasdaqGS:RUBY) is a biopharmaceutical company pioneering the development of a new class of medicines called Red Cell Therapeutics™. The Company's proprietary RED PLATFORM™ was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and ready-to-use cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Rubius' initial focus is to advance RCT™ product candidates for the treatment of rare diseases, cancer and autoimmune diseases by leveraging three distinct therapeutic modalities — cellular shielding, potent cell-cell interaction and tolerance induction

VACCINEX, INC. (NasdqGM: VCNX) is a clinical-stage immunotherapy company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders, with currently active clinical trials in Non-Small Cell Lung Cancer and Huntington's disease. Vaccinex is based in Rochester, New York.

New Mining Companies

Zenith Exploration Inc. (CSE:ZX) is a resource exploration issuer that acquires and explores mineral properties. Zenith's principal property is in Quebec and its secondary property is in BC. The Company intends to explore and develop these properties.

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

About Investorideas.com - News that Inspires Big Investing Ideas

Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Learn more about our news, PR and social media services at Investorideas.com

https://www.investorideas.com/Investors/Services.asp

To sponsor one of our podcasts or columns or be a guest call us today!

Contact Investorideas.com

https://www.investorideas.com/About/Contact.asp

800-665-0411

Friday, August 31, 2018

Investorideas.com - #Cannabis, #Biotech, #China and #Mining #Stocks added to Investor Ideas

#Cannabis, #Biotech, #China
and #Mining #Stocks added to Investor Ideas

Point Roberts, WA, Delta BC – August 31, 2018 –
(Investorideas.com Newswire) Investorideas.com, a global news source and
leading investor resource covering actively traded sectors announces this
week’s additions to its global stock
directories in cannabis, biotech, China-Asia and mining.

Investorideas.com tracks companies in high-profile
trading sectors and makes ongoing additions to its stock directories for its members. Free previews of all
directories are available to the public with full login access only accessible
to members.

Read this in full at https://www.investorideas.com/news/2018/main/08311Stocks.asp

The newest cannabis companies are involved in
hemp-based CBD products and medical cannabis respectively.

The latest biotech companies include a medical
device company, a gene therapy company and a pharma company involved in developing anti-infectives.

New China-Asia companies are involved in the
education and IT-Fintech sectors. The
newest mining company is working in Mexico at the Rebeico Gold-Copper project.

New Cannabis Companies:

Charlotte's Web Holdings, Inc. (CSE: CWEB) is a market
leader in the production and distribution of innovative hemp-based, CBD
wellness products. Through its vertically integrated business model,
CWEB strives to improve customers’ lives and meet their demands for
stringent product quality, efficacy and consistency.

Pure Global Cannabis Inc. (TSX:PURE.V; OTC: PRCNF) is a vertically-integrated, growth-oriented life sciences
cannabis company led by experienced pharma-industry, horticultural, consumer
packaged goods (CPG), and supply chain experts. The Company's wholly owned
subsidiary, PureSinse Inc., is a licensed producer under the Access to Cannabis
for Medical Purposes Regulations (ACMPR) focused on producing cannabis products
for medical, wellness, health & beauty, natural health, and future legal
adult use markets.

Investorideas.com
cannabis/marijuana and hemp news and investing content now includes our daily potcasts^CM ; podcasts featuring cannabis news and stocks to watch plus
insight from thought leaders and experts. Recent
interviews include Montel Williams, The Arcview Group, Electrum Partners and
the CEO of Cronos Group Inc. (NASDAQ: CRON).

The cannabis stocks potcast (podcast)
is also released with an accompanying written transcript. Learn more and sign up at http://www.investorideas.com/Audio/Potcasts.aspOr www.potcasts.ca

To sponsor our daily podcast for the month or to be an expert guest
please contact us!

http://www.investorideas.com/About/Contact.asp

New Biotech Companies

Hancock
Jaffe Laboratories, Inc. (NasdaqCM:HJLI) specializes in developing and manufacturing bioprosthetic medical
devices that establish improved standards of care for treating cardiac and
vascular diseases. HJLI currently has three product candidates: the porcine
tissue based VenoValve®, which is intended to be surgically implanted in the
deep venous system of the leg to treat Chronic Venue Insufficiency; the
CoreoGraft®, a bovine tissue based off the shelf conduit intended to be used
for coronary artery bypass surgery, and a porcine tissue based heart valve,
which based upon its relatively small size and increased output, is an ideal
candidate for pediatric aortic/mitral valve replacement.

Iterum
Therapeutics plc (NasdaqGM:ITRM) is a clinical-stage pharmaceutical company
dedicated to developing differentiated anti-infectives aimed at combatting the
global crisis of multi-drug resistant pathogens to significantly improve the
lives of people affected by serious and life-threatening diseases around the
world. Iterum Therapeutics is advancing its first compound, sulopenem, a novel
penem anti-infective compound with oral and IV formulations that has
demonstrated potent in vitro activity against a wide variety of gram-negative,
gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum
Therapeutics has received QIDP designations for its oral and IV formulations
for the treatment of uUTI, complicated urinary tract infection and complicated
intra-abdominal infection.

MeiraGTx
Holdings plc (NasdaqGS:MGTX) is a vertically integrated, clinical stage gene
therapy company with four ongoing clinical programs and a broad pipeline of
preclinical and research programs. MeiraGTx has core capabilities in viral
vector design and optimization and gene therapy manufacturing, as well as a
potentially transformative gene regulation technology. Led by an experienced
management team, MeiraGTx has taken a portfolio approach by licensing, acquiring
and developing technologies that give depth across both product candidates and
indications. MeiraGTx’s initial focus is on three distinct areas of unmet
medical need: inherited retinal diseases, severe forms of xerostomia and
neurodegenerative diseases. Though initially focusing on the eye, salivary
gland and central nervous system, MeiraGTx intends to expand its focus in the
future to develop additional gene therapy treatments for patients suffering
from a range of serious diseases.

New China-Asia Companies

Ambow Education Holding Ltd. (NYSE:AMBO) is a leading national provider of educational and
career enhancement services in China, offering high-quality, individualized
services and products. With its extensive network of regional service hubs
complemented by a dynamic proprietary learning platform and distributors, Ambow
provides its services and products to students in 30 out of the 31 provinces
and autonomous regions within China.

CLPS Incorporation (NasdaqCM: CLPS)
is a global leading information technology ("IT"), consulting and
solutions service provider focusing on the banking, insurance and financial
sectors. The Company serves as an IT solutions provider to a growing network of
clients in the global financial industry, including large financial institutions
in the US, Europe, Australia and Hong Kong and their PRC-based IT centers. The
Company maintains eleven delivery and/or research & development centers to
serve different customers in various geographic locations. Mainland China
centers are located in Shanghai, Beijing, Dalian, Tianjin, Chengdu, Guangzhou
and Shenzhen. The remaining four global centers are located in Hong Kong,
Taiwan, Singapore and Australia.

New Mining Companies

Ridgestone
Mining Inc. (TSX:RMI.V) is a TSX Venture Exchange -listed junior mineral
exploration company with offices in Taipei and Vancouver, B.C. The Company's
focus is on precious metals and copper in Sonora, Mexico, and specifically the
Rebeico Gold-Copper project.

The directories are not meant as recommendations
but as a research tool to discover opportunities and trading ideas in a
particular sector.

Membership: Investorideas.com stock directories are part of the
membership program on the site, accessed either by login and password or
available in PDF format. The directories include stocks trading on the
TSX, OTC, NASDAQ, NYSE and other recognized global stock exchanges, giving
retail investors a wide variety of stocks to review.

http://www.investorideas.com/membership/

About
Investorideas.com - News that Inspires Big Investing Ideas

Investorideas.com is a
recognized news source publishing third party news and press releases plus we
create original financial content. Learn about investing in stocks and
sector trends from Investorideas.com with our news alerts , articles , podcasts and videos talking
about cannabis, crypto, technology including AI and IoT ,
mining ,sports biotech, water, renewable energy and more . Investorideas.com
original branded content includes the daily Crypto Corner and Podcast, Play by Play sports and stock news column, Investor
Ideas #Potcasts
#Cannabis News and Stocks on the Move podcast and column, Cleantech and
Climate Change Podcast and the Stock Guru daily podcast on Support and
Resistance Trading.

Disclaimer/Disclosure: Investorideas.com is a
digital publisher of third party sourced news, articles and equity research as
well as creates original content, including video, interviews and articles.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Our site does not make recommendations for purchases or
sale of stocks, services or products. Nothing on our sites should be construed
as an offer or solicitation to buy or sell products or securities. All
investment involves risk and possible loss of investment. This site is
currently compensated for news publication and distribution, social media and
marketing, content creation and more. Contact each company directly regarding
content and press release questions. Disclosure is posted for each compensated
news release, content published /created if required but otherwise the news was
not compensated for and was published for the sole interest of our readers and
followers. More disclaimer and disclosure info: http://www.investorideas.com/About/Disclaimer.asp.

Additional info regarding
BC Residents and global Investors: Effective September 15 2008 - all BC
investors should review all OTC and Pink sheet listed companies for adherence
in new disclosure filings and filing appropriate documents with Sedar. Read for
more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to
regulations of each country.

Please read
Investorideas.com privacy policy: http://www.investorideas.com/About/Private_Policy.asp

Learn more about our news, PR and social media
services at Investorideas.com

http://www.investorideas.com/Investors/Services.asp

To sponsor one of our
podcasts or columns or be a guest call us today!

Contact
Investorideas.com

http://www.investorideas.com/About/Contact.asp

800-665-0411

Disclaimer

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.

More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Biotech/Medical Tech Stock News from Investorideas.com

Investorideas.com newswire, breaking biotechnology and pharma news

Friday, December 14, 2018

Investorideas.com - Investor Ideas Adds New Stocks in #Cannabis and #Biotech $NTFU, $PYX, $BOSS.C, $MRNA

Investor Ideas Adds New Stocks in #Cannabis and #Biotech $NTFU, $PYX, $BOSS.C, $MRNA

Friday, October 26, 2018

Investorideas.com - Investor Ideas Adds New #Nasdaq IPOs in #Biotech (Nasdaq: $ALLO, $EQ, $GH, $KOD, $PRNB, $YMAB) & Newly Listed #CSE Stocks

Investor Ideas Adds New #Nasdaq IPOs in #Biotech (Nasdaq: $ALLO, $EQ, $GH, $KOD, $PRNB, $YMAB) & Newly Listed #CSE Stocks

CSE-Listed Stocks in #Mining, #Energy and #Nanotech (CSE: $CRES, $DLRY, $KAL, $SENS, $SONA)

Thursday, October 18, 2018

Investorideas.com - #HealthcareStock News: China Infrastructure Construction Corp. (OTCPK: $CHNC) and America's Advanced Wellness Centers, LLC (AAWC) Enter Into Acquisition Agreement

#HealthcareStock News: China Infrastructure Construction Corp. (OTCPK: $CHNC) and America's Advanced Wellness Centers, LLC (AAWC) Enter Into Acquisition Agreement

BiotechIndustryStocks.com - investing ideas in biotechnology stocks, medical technology and life sciences

Like Biotech Stocks? View our Biotech Stocks Directory

Get News Alerts on Biotech Stocks

Friday, October 12, 2018

Investorideas.com - Investor Ideas adds Nasdaq #Biotech #IPOs and CSE #Mining IPO Stocks to Directories (NASDAQ: $ADIL), (NASDAQ: $ALLK) (NASDAQ: $AQST), (CSE: $ZX.C)

Investor Ideas adds Nasdaq #Biotech #IPOs and CSE #Mining IPO Stocks to Directories (NASDAQ: $ADIL), (NASDAQ: $ALLK) (NASDAQ: $AQST), (CSE: $ZX.C)

Friday, August 31, 2018

Investorideas.com - #Cannabis, #Biotech, #China and #Mining #Stocks added to Investor Ideas